Astria Therapeutics to Present at Upcoming Global Angioedema Forum

ATXS 09.27.2024

Full Press ReleaseSEC FilingsOur ATXS Tweets

About Gravity Analytica

Recent News

  • 01.23.2025 - Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
  • 01.13.2025 - Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
  • 01.03.2025 - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
PDF Version

BOSTON--(BUSINESS WIRE)--Sep. 27, 2024--Astria Therapeutics, Inc.(Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at theGlobal Angioedema Forum(GAF) inCopenhagen, DenmarkonOctober 4-5, 2024.

  • Dr.Aleena Banerji, M.D., Associate Professor of Medicine atHarvard Medical Schooland Clinical Director of the Allergy and Immunology Unit atMassachusetts General Hospital, will present information on ALPHA-SOLAR, a long-term open-label trial of navenibart (STAR-0215) in people living withHAE, inan encore presentation of a poster titled “Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215.” The poster session will take place onFriday, October 4at6:00pm CEST.
  • Dr.William Lumry, M.D., Clinical Professor of Internal Medicine at theUniversity of Texas Health Science CenteratDallas, will present results from the Phase 1b/2 trial of navenibart (STAR-0215) in an encore presentation of a poster titled “ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes.” The presentation will take place during a session titled “Emerging Treatment Options” onSaturday, October 5at9:30am CEST.

AboutAstria Therapeutics:Astria Therapeuticsis a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website,www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20240927312997/en/

Astria Contact:Investor Relations and Media:Elizabeth Higginsinvestors@astriatx.com

Source:Astria Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com